Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31596300 | 0.98 | TDP1 (0.76) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL154267 | 0.90 | TDP1 (0.72) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL11223785 | 0.89 | L3MBTL1 (0.70) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL15316696 | 0.89 | L3MBTL1 (1.00) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL8619264 | 0.88 | CES1 (0.64) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL497371 | 0.88 | KEAP1 (0.73) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL8664876 | 0.87 | HDAC1 (0.67) | TDP1L3MBTL1KEAP1ALDH1A1CES2 | |
| SCHEMBL6512327 | 0.86 | CES1 (0.61) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL107423 | 0.86 | KEAP1 (0.70) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 | |
| SCHEMBL712597 | 0.86 | KEAP1 (0.70) | TDP1L3MBTL1KEAP1ALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| CN-113905890-B | Method for transferring an embossed structure to a coating composition by pretreatment of an embossing tool for transfer | 巴斯夫涂料有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| CN-112969733-B | Aqueous base formulations based on functionalized polyurethanes | 巴斯夫欧洲公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-20230348396-A1 | HYDROXYBENZAMIDE DERIVATIVES AND METHODS OF USE IN TREATING DIABETES | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230295678-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2023-09-21 | — | — | US | disclosed |
| US-4983739-A | Optically active styrene compounds | CIBA-GEIGY CORPORATION (US) | 1991-01-08 | — | — | US | disclosed |
| US-4954592-A | Optically active styrene derivatives, polymers obtained from these, complexes with iridium(I) and their use | CIBA-GEIGY CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4904790-A | Optically active styrene compounds substituted by a pyridinyl group | CIBA-GEIGY CORPORATION (US) | 1990-02-27 | — | — | US | disclosed |
| US-4891412-A | Optically active styrene derivatives, polymers obtained from these, complexes with iridium(I) and their use | CIBA-GEIGY CORPORATION (US) | 1990-01-02 | — | — | US | disclosed |
| US-4800224-A | Optically active styrene derivatives, polymers obtained from these, complexes with iridium(I) and their use | CIBA-GEIGY CORPORATION (US) | 1989-01-24 | — | — | US | disclosed |
| EP-0251994-A1 | Optically active styrene derivatives, polymers therefrom, complexes with iridium (I) and their use | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
| EP-0239109-A2 | Phosphonate angiotensin converting enzyme inhibitors | E.R. Squibb & Sons, Inc. (US) | 1987-09-30 | — | — | EP | disclosed |
| EP-0080721-A2 | Diphenylalkanoamine derivatives, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-06-08 | — | — | EP | disclosed |
| US-4347248-A | DIURETICS | AMERICAN CYANAMID COMPANY (US) | 1982-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | TDP1 2746/4885L3MBTL1 4522/4885KEAP1 1425/4885 |
| US-20230348396-A1 | HYDROXYBENZAMIDE DERIVATIVES AND METHODS OF USE IN TREATING DIABETES | HSPA5, IAPP, TFEB | TDP1 1865/4885L3MBTL1 644/4885KEAP1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.